Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 1.00 |
| ▸ | DDB1 | Q16531 | 18/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31704153 | 1.00 | CRBN (1.00) | CRBNDDB1POLB | |
| SCHEMBL31704110 | 1.00 | CRBN (1.00) | CRBNDDB1POLB | |
| SCHEMBL19370870 | 0.90 | CRBN (0.81) | CRBNDDB1POLB | |
| SCHEMBL7828080 | 0.81 | CRBN (0.70) | CRBNDDB1POLB | |
| SCHEMBL7827796 | 0.81 | CRBN (0.70) | CRBNDDB1POLB | |
| SCHEMBL25026926 | 0.81 | CRBN (0.70) | CRBNDDB1POLB | |
| SCHEMBL1553566 | 0.81 | CRBN (1.00) | CRBNDDB1POLB | |
| SCHEMBL19586225 | 0.81 | CRBN (1.00) | CRBNDDB1POLB | |
| SCHEMBL8182409 | 0.81 | CRBN (0.70) | CRBNDDB1POLB | |
| SCHEMBL25026923 | 0.81 | CRBN (0.70) | CRBNDDB1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137677-A1 | PROTACS USEFUL AGAINST THE MAIN PROTEASE SARS-COV-2 | TOCRIS COOKSON LTD (GB) | 2026-05-21 | — | — | US | claimed |
| EP-4673438-A1 | PROTEOLYSIS-TARGETING CHIMERAS | Tocris Cookson Limited (GB) | 2026-01-07 | — | — | EP | claimed |
| EP-4598582-A1 | PROTEOLYSIS-TARGETING CHIMERAS AGAINST THE PAPAIN-LIKE PROTEASE OF SARS-COV-2 | Tocris Cookson Limited (GB) | 2025-08-13 | — | — | EP | claimed |
| EP-4598914-A1 | PROTACS USEFUL AGAINST THE MAIN PROTEASE SARS-COV-2 | Tocris Cookson Limited (GB) | 2025-08-13 | — | — | EP | claimed |
| WO-2024238872-A2 | ISOINDOLINONE-GLUTARIMIDE ANTIBODY CONJUGATES, AND USES THEREOF | FIREFLY BIO, INC. (US) | 2024-11-21 | — | — | WO | claimed |
| WO-2024222726-A1 | DEGRADATION AGENT FOR CYCLIN-DEPENDENT KINASE (CDK) 12/13, COMPOSITION AND USE THEREOF | 浙江大学 | 2024-10-31 | — | — | WO | claimed |
| WO-2024180157-A1 | PROTEOLYSIS-TARGETING CHIMERAS | TOCRIS COOKSON LIMITED (GB) | 2024-09-06 | — | — | WO | claimed |
| WO-2024074848-A1 | PROTACS USEFUL AGAINST THE MAIN PROTEASE SARS-COV-2 | TOCRIS COOKSON LIMITED (GB) | 2024-04-11 | — | — | WO | claimed |
| WO-2024074849-A1 | PROTEOLYSIS-TARGETING CHIMERAS AGAINST THE PAPAIN-LIKE PROTEASE OF SARS-COV-2 | TOCRIS COOKSON LIMITED (GB) | 2024-04-11 | — | — | WO | claimed |
| CN-116675731-A | Small molecule conjugate of targeted cyclin-dependent kinase 12/13 and application thereof | 浙江大学 | 2023-09-01 | — | — | CN | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20260137677-A1 | PROTACS USEFUL AGAINST THE MAIN PROTEASE SARS-COV-2 | TOCRIS COOKSON LTD (GB) | 2026-05-21 | — | — | US | disclosed |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-0888304-B1 | SUBSTITUTED 3-ARYL-3-CARBOXYALKYL GLUTARAMIDES, METHOD FOR PREPARING SAME BY 4-ARYLO-4-CYANOHEPTANE DICARBOXYLIC ACID CYCLISATION, AND USE THEREOF FOR PREPARING 3-ARYL-3-HYDROXYALKYLPIPERIDINES | SANOFI SYNTHELABO (FR) | 2001-10-04 | — | — | EP | disclosed |
| EP-0417143-A1 | CYCLIC LACTAMS FOR CHOLESTEROL AND ATHEROSCLEROSIS CONTROL | THE UPJOHN COMPANY (US) | 1991-03-20 | — | — | EP | disclosed |
| WO-1989011856-A2 | CYCLIC LACTAMS FOR CHOLESTEROL AND ATHEROSCLEROSIS CONTROL | THE UPJOHN COMPANY (US) | 1989-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | NEDD4, UBE3A, UBE3C | CRBN 11/4885DDB1 279/4885POLB 4356/4885 |
| US-20260137677-A1 | PROTACS USEFUL AGAINST THE MAIN PROTEASE SARS-COV-2 | XIAP, MDM2, SARS1 | CRBN 4/4885DDB1 429/4885POLB 2039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.